Shared on 22 Oct 25
Fair value Increased 4.91%Analysts Lift Embla Medical hf Price Target on Stronger Growth and Improved Margins
Analysts have raised their price target for Embla Medical hf. from $35.65 to $37.40, citing improved revenue growth and higher profit margin forecasts.
Shared on 19 Sep 25
Fair value Increased 4.24%Portfolio Expansion And Reimbursement Coverage Will Strengthen Medtech Future
The consensus Analyst Price Target for Embla Medical hf has risen to DKK35.65, primarily reflecting a substantial increase in the future P/E ratio while net profit margin remains stable. What's in the News Completed repurchase of 923,277 shares (0.22%) for $4.3 million under previously announced buyback.
Shared on 01 May 25
Fair value Increased 6.94%Portfolio Expansion And Reimbursement Coverage Will Strengthen Medtech Future
Shared on 23 Apr 25
Fair value Decreased 8.81%New Product Launches And Manufacturing Improvements Will Shape Future Reach
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 17 Apr 25
Fair value Decreased 1.21%New Product Launches And Manufacturing Improvements Will Shape Future Reach
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 09 Apr 25
Fair value Decreased 6.70%New Product Launches And Manufacturing Improvements Will Shape Future Reach
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 02 Apr 25
Fair value Increased 3.40%New Product Launches And Manufacturing Improvements Will Shape Future Reach
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 26 Mar 25
Fair value Decreased 2.72%New Product Launches And Manufacturing Improvements Will Shape Future Reach
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 19 Mar 25
Fair value Increased 1.10%New Product Launches And Manufacturing Improvements Will Shape Future Reach
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 12 Mar 25
Fair value Increased 9.18%New Product Launches And Manufacturing Improvements Will Shape Future Reach
AnalystConsensusTarget has increased profit margin from 9.7% to 10.7% and increased shares outstanding growth rate from -0.0% to 0.0%.